Edition:
India

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

6.07USD
3 Aug 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.07
Open
$5.93
Day's High
$6.24
Day's Low
$5.85
Volume
94,153
Avg. Vol
130,480
52-wk High
$7.34
52-wk Low
$1.76

Latest Key Developments (Source: Significant Developments)

Five Prime Therapeutics Reports Q1 Loss Per Share Of $0.57
Friday, 8 May 2020 

May 7 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS REPORTS FIRST QUARTER 2020 RESULTS.Q1 LOSS PER SHARE $0.57.Q1 EARNINGS PER SHARE ESTIMATE $-0.67 -- REFINITIV IBES DATA.FIVE PRIME THERAPEUTICS - COLLABORATION AND LICENSE REVENUE FOR Q1 OF 2020 INCREASED BY $3.1 MILLION, OR 58%, TO $8.4 MILLION FROM $5.3 MILLION FOR Q1 OF 2019.EXPECTS FULL-YEAR 2020 NET CASH USED IN OPERATING ACTIVITIES TO BE BETWEEN $77 AND $82 MILLION.FIVE PRIME THERAPEUTICS - AFFIRMS PREVIOUSLY ISSUED GUIDANCE TO END 2020 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES BETWEEN $77 AND $82 MILLION.  Full Article

Five Prime Therapeutics Appoints Tom Civik As Chief Executive Officer
Tuesday, 14 Apr 2020 

April 14 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS APPOINTS TOM CIVIK AS CHIEF EXECUTIVE OFFICER.FIVE PRIME THERAPEUTICS INC - TOM CIVIK SUCCEEDS WILLIAM RINGO WHO WILL CONTINUE AS CHAIRMAN.FIVE PRIME THERAPEUTICS INC - CIVIK SUCCEEDS WILLIAM RINGO WHO WILL CONTINUE AS CHAIRMAN.FIVE PRIME THERAPEUTICS INC - REMAINS ON TRACK TO ACHIEVE PROGRAM MILESTONES AND CLINICAL DATA DISCLOSURES IN 2020.  Full Article

Five Prime Therapeutics Reports Q4 Loss Per Share $0.89
Friday, 28 Feb 2020 

Feb 27 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 RESULTS.Q4 LOSS PER SHARE $0.89.Q4 EARNINGS PER SHARE ESTIMATE $-0.96 -- REFINITIV IBES DATA.FIVE PRIME THERAPEUTICS - EXPECTS FULL-YEAR 2020 NET CASH USED IN OPERATING ACTIVITIES TO BE BETWEEN $77 AND $82 MILLION.  Full Article

Five Prime Therapeutics Licenses Antibodies To Seattle Genetics For Use In Novel Antibody Drug Conjugate Programs
Wednesday, 19 Feb 2020 

Feb 19 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS LICENSES ANTIBODIES TO SEATTLE GENETICS FOR USE IN NOVEL ANTIBODY DRUG CONJUGATE (ADC) PROGRAMS.FIVE PRIME THERAPEUTICS - RECEIVES $5 MILLION UPFRONT PAYMENT.FIVE PRIME THERAPEUTICS - ELIGIBLE TO RECEIVE UP TO COMBINED TOTAL OF $525 MILLION IN FUTURE MILESTONE PAYMENTS FOR FIRST TWO ADC PRODUCT CANDIDATES.  Full Article

BVF Partners Reports 21.4% Stake In Five Prime Therapeutics As Of December 20
Friday, 27 Dec 2019 

Dec 27 (Reuters) - Five Prime Therapeutics Inc ::BVF PARTNERS LP REPORTS 21.4% STAKE IN FIVE PRIME THERAPEUTICS INC AS OF DECEMBER 20 - SEC FILING.BVF PARTNERS LP SAYS PURCHASED FIVE PRIME THERAPEUTICS' SHARES BASED ON BELIEF THAT SHARES, WHEN PURCHASED, WERE "UNDERVALUED".  Full Article

Five Prime Therapeutics Reports Third Quarter 2019 Results
Thursday, 7 Nov 2019 

Nov 6 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS REPORTS THIRD QUARTER 2019 RESULTS.Q3 LOSS PER SHARE $1.03.Q3 EARNINGS PER SHARE ESTIMATE $-0.95 -- REFINITIV IBES DATA.COLLABORATION AND LICENSE REVENUE FOR Q3 DECREASED BY $2.8 MILLION, OR 48.3%, TO $3.0 MILLION.EXPECTS FULL-YEAR 2019 NET CASH USED IN OPERATING ACTIVITIES TO BE BETWEEN $117 AND $122 MILLION.ESTIMATES ENDING 2019 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES BETWEEN $148 AND $153 MILLION.Q3 REVENUE VIEW $5.2 MILLION -- REFINITIV IBES DATA.  Full Article

Five Prime Therapeutics Announces Management Transition
Friday, 20 Sep 2019 

Sept 19 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS ANNOUNCES MANAGEMENT TRANSITION.SAYS WILLIAM RINGO APPOINTED INTERIM CEO.RINGO WILL SUCCEED CHIEF EXECUTIVE OFFICER AND BOARD MEMBER ARON KNICKERBOCKER.RINGO WILL CONTINUE TO SERVE AS CHAIRMAN OF FIVE PRIME'S BOARD OF DIRECTORS.KNICKERBOCKER RESIGNED FROM COMPANY.  Full Article

Five Prime Therapeutics Q1 Loss Per Share $1.02
Thursday, 9 May 2019 

May 8 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS REPORTS FIRST QUARTER 2019 RESULTS.Q1 LOSS PER SHARE $1.02.Q1 EARNINGS PER SHARE ESTIMATE $-1.06 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $237.0 MILLION AS OF MARCH 31, 2019.FIVE PRIME EXPECTS FULL-YEAR 2019 NET CASH USED IN OPERATING ACTIVITIES TO BE BETWEEN $117 AND $122 MILLION.ESTIMATES ENDING 2019 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES BETWEEN $148 AND $153 MILLION.  Full Article

Five Prime Therapeutics Inc Files For Stock Shelf Of Up To $250 Million
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS INC FILES FOR STOCK SHELF OF UP TO $250 MILLION .  Full Article

Five Prime Therapeutics Announces Third Quarter 2018 Financial Results
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.37.Q3 EARNINGS PER SHARE VIEW $-1.15 -- THOMSON REUTERS I/B/E/S.COLLABORATION AND LICENSE REVENUE FOR Q3 OF 2018 DECREASED BY $2.5 MILLION, OR 30%, TO $5.8 MILLION FROM $8.3 MILLION FOR Q3 OF 2017.FIVE PRIME EXPECTS FULL-YEAR 2018 NET CASH USED IN OPERATING ACTIVITIES TO BE LESS THAN $135 MILLION.NOW ESTIMATES ENDING 2018 WITH APPROXIMATELY $265 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.  Full Article